Check out our CEO, Jordan Pollack stage delivering our story live on stage at #LSIEurope24. Thank you to LSI for putting together such a great meeting and giving us the opportunity to share exactly how we are advancing treatments for crossing and opening chronic occlusions in veins. This is a massive untapped market with even more innovation potential as we work to get our novel device, Traversa, to market soon. We'll be sure to see you at LSI next year. Daniel Arad Ben Friesem Irina Kiniaeva Yaron ( Ronnie ) Eshel Shraga Ciner MEDX Xelerator LP Itzhak Kricheli
VeinWay Ltd. is advancing treatment for venous chronic total occlusions with its specialized device, Traversa. Designed specifically to overcome the challenges of crossing blocked veins, Traversa provides physicians with a tool purpose-built to navigate complex venous blockages that are often difficult and time-intensive to cross. Crossing occluded veins is a demanding process, frequently resulting in failed attempts due to the complexity of the blockages. Traversa aims to change this by expanding the capabilities of physicians to safely and efficiently access obstructed veins. The device integrates several unique features to enhance its effectiveness: a steerable needle, offering precise navigational control even in complex pathways; a 6mm balloon that anchors Traversa securely within the vein to facilitate deeper needle penetration; and a braided catheter that balances durability with flexibility, ensuring the catheter maintains strength without compromising its maneuverability. Want to learn more about VeinWay? Catch Jordan Pollack’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.